Therefore, they believe that the SLC34A2-miR-25-Gsk3β pathway is a possible pathway regulating the properties of GCSCs and GC progression and is expected to be a potential target for the treatment of GC (112). The gene discussed is GSK3B; the disease is gastric cancer.